Published August 27 & September 3 (EPO); August 21 & 28 (WO)

Alphahelix WO 97/30086 RET oncogene deletion Uppsala, Sweden Nucleotide sequence including a typical deletion in the proto-oncogene RET; for diagnosis and therapy.

Amsterdam Support Diagnostics WO 97/30152 DNA separation method Utrecht, Netherlands Methods for separating single-stranded and double-stranded DNA using solid supports.

Applied Res. Systems WO 97/30161 Hybrid protein hormone Curacao, Netherlands Antilles Hybrid protein with a receptor or ligand domain linked to a heterodimeric protein hormone subunit; for therapeutics.

Ariad Pharma WO 97/31113 Phosphopeptide binding inhibitors Cambridge, Mass. Cell-based assay for identifying inhibitors of the interaction of phosphopeptide binding pairs.

Asahi EPO 791 650 Stabilized reverse transcriptase Osaka, Japan Storage of reverse transcriptase with stabilizing agents; for increased temperature stability.

Assoc. Molec. Genetics Res. WO 97/31108 Modified glucocorticoid receptor Paris Nuclear glucocorticoid receptor modified near the binding site; for stronger induction by synthetic ligands.

Boehringer Ingelheim WO 97/30170 Cationic transfection Ingelheim, Germany Transfection composition containing cationic lipids and membrane-active acid peptides.

Bristol-Myers Squibb WO 97/31104 Candida albicans profilin gene Princeton, N.J. Gene for Candida albicans profilin, encoded protein, vectors, host cells; for detecting anti-fungal agents.

California, Univ. of EPO 792 931 Cancer suppressor replacement Alameda, Calif. Location and replacement of defective cancer suppressing genes; for animal models and cancer treatment.

California, Univ. of WO 97/30168 Neuronal cell immortalization Oakland, Calif. Retroviral vector with a v-myc oncogene and cytomegalovirus promoter; for immortalizing neuronal progenitor cells.

Chiron WO 97/29771 Recombinant cholera vaccine Siena, Italy Detoxified muteins of cholera toxin that remain immunogenic; for vaccination.

Chiron WO 97/30155 Vascular gene therapy Emeryville, Calif. Fibroblast growth factor gene lacking its signal sequence; for vascular disease gene therapy without carcinogenesis.

Chugai WO 97/30173 Tumor endothelial cell antibodies Tokyo Monoclonal antibodies that recognize antigens on the surface of endothelial cells in tumor blood vessels; for therapy.

Coles, J.G. et al. WO 97/31107 Apoptotic serum lectins Toronto Lectins from human serum that cause apoptosis; for treating xenograft rejection and cancers.

Edinburgh, Univ. of WO 97/30151 ES cell differentiation cytokine Edinburgh, U.K. Cytokine that inhibits embryonic stem (ES) cell differentiation; for manipulating ES cells and making transgenics.

Fred Hutchinson Cancer Res. Ctr. WO 97/30169 High titer retrovirus Seattle Retroviral packaging cells that produce replication-deficient vector particles at high titer.

German Hlth. & Welfare Res. Ctr. WO 97/30153 Epithelial cancer probe Oberschleissheim, Germany Probe that hybridizes with the pax9 gene; for diagnosis and therapy of cancers in multi-layered epithelia.

Harvill, E.T. et al. WO 97/30089 Cytokine-antibody fusion protein Los Angeles, Calif. Fusion protein containing a cytokine and an immunoglobulin; for potentiation of immune response and screening antigens.

Human Genome Sciences WO 97/31098 Human chemokine genes Rockville, Md. Human chemokine genes, encoded proteins, antagonists; for treating autoimmunity and cancer.

Icos WO 97/31099 ß2-integrin a subunit gene Bothell, Wash. Gene for human ß2-integrin a subunit, encoded protein, fusion proteins containing fragments.

Immunex WO 97/31010 Inflammation inhibition Seattle DF1 polypeptides, encoding genes; for inhibiting prostaglandin synthesis and treating inflammation.

Incyte WO 97/30157 Myeloid differentiation gene Palo Alto, Calif. Myeloid terminal differentiation response gene, encoded protein, antisense, antibodies.

Indian Council Sci. & Ind. Res. EPO 792 934 Bacterial expression system New Delhi, India Bacterial expression system controlled by osmotic stress; for expressing recombinant proteins.

Inst. Pharma Res. EPO 791 651 Biological material storage Riehen, Switzerland Methods for handling and storing materials from complex biological systems [in German].

Introgene WO 97/3111 Organic anion transporters Rijswijk, Netherlands Organic anion transporter proteins, encoding genes, expression vectors; for gene therapy.

Isis Pharma WO 97/29780 Protein kinase C oligos Carlsbad, Calif. Methoxyethoxy oligonucleotides targeted to protein kinase C genes; for inhibiting enzyme expression.

Japan Tobacco WO 97/31106 Membrane phospholipid modification Tokyo Modification of membrane phospholipids of living cells by transfecting with phospholipase D antisense genes.

Jean Dausset Fdn. WO 97/30178 Trinucleotide repeat diseases Paris DNA sequences with repeat codons; for identifying trinucleotide repeats and associated diseases.

Johns Hopkins Univ. WO 97/31112 Modified potassium channel Baltimore, Md. Modified subunit of a potassium channel, encoding gene; for modulating physiological function of the channel.

LG Chemical WO 97/30147 Varicella zoster production Seoul, S. Korea Human embryonic lung fibroblast cell line for the production of Varicella zoster virus.

Maastricht Univ. WO 97/31117 Combined cytomegalovirus antigen Maastricht, Netherlands Combined antigen having portions of several human cytomegalovirus proteins; for diagnostics and immunoprotection.

Merck WO 97/31015 Rat ob receptor gene Rahway, N.J. Rat ob receptor gene and its alleles, encoded proteins, expression vectors, host cells.

Merck WO 97/31115 Synthetic HIV genes Rahway, N.J. Synthetic HIV genes and encoded proteins; for immunoprotection and vaccination against HIV.

Michigan, Univ. of WO 97/31012 Conserved gene region primers Ann Arbor, Mich. Primer sets that amplify conserved regions of specific mammalian genes, production methods.

Mochida Pharma WO 97/31109 Meltrins Tokyo Meltrins, encoding genes, antagonists, expression vectors; for modulating myoblast adhesion.

NIH (Natl. Inst. Hlth.) WO 97/31116 Modified frog ribonucleases Bethesda, Md. Humanized and recombinant forms of a ribonuclease derived from frog (Rana pipiens) oocytes.

Novo Nordisk WO 97/30148 Less allergenic peptides Bagsvaerd, Denmark Polypeptide conjugates with reduced allergenicity; for making personal care products.

Pangenetics WO 97/30150 Peptide antigen library Amsterdam, Netherlands Generation of a peptide antigen library from a parental nucleotide sequence; for inducing immunological tolerance.

Pasteur Inst. WO 97/30158 & 30159 Malaria vaccine Paris Recombinant protein having the C-terminal fragment of Plasmodium falciparum surface protein; for malaria vaccine.

Pennsylvania, Univ. of WO 97/30167 Liver gene therapy Philadelphia Gene therapy using at least one urea cycle enzyme gene; for treating liver disorders.

Perkin-Elmer WO 97/31126 PCR-based HLA typing Foster City, Calif. Methods and reagents for tissue typing HLA class I gene antigens using PCR techniques.

PPL Therapeutics EPO 791 652 Recombinant proteins from milk Edinburgh, U.K. Transgenic mammals that express recombinant proteins in their milk using a whey protein gene-based vector.

Precision System Science WO 97/31105 Magnetic DNA isolation Tokyo Treating biopolymers and microorganisms with magnetic particles; for isolating DNA.

Res. Inst. Genetic & Human Therapy WO 97/31119 Lymph system immunotherapy Bethesda, Md. Transduction of lymph system cells with vectors expressing attenuated viruses; for on site immunotherapy.

Richt, J.A. EPO 791 654 Borna disease vaccine Langgons-Niederkleen, Germany Borna disease virus antigenic proteins, encoding genes; for test kits and vaccination.

Sanko Junyaku EPO 792 932 DNA precipitation method Tokyo Coprecipitant for nucleic acid that does not inhibit PCR reactions and is visible when precipitated.

Schering Biotech EPO 791 653 Fc-gamma receptor III Palo Alto, Calif. Soluble and membrane-bound human Fc-gamma receptor III, variants, encoding genes; for treating thrombocytopenia.

SmithKline Beecham WO 97/30070 & 31114 Staphylococcus inhibitors King of Prussia, Pa. Staphylococcal genes and encoded proteins, biosynthetic inhibitors; for antimicrobial therapy.

SmithKline Beecham WO 97/30149 ERA polypeptides King of Prussia, Pa. ERA polypeptides, encoding genes, recombinant production techniques; for bacterial infection protection.

Stanford Univ. WO 97/30587 T cell response suppression Palo Alto, Calif. Vaccination with DNA encoding T cell receptor variable region; for suppression of T cell response.

Sumitomo Electric WO 97/31110 Transcription activator proteins Osaka, Japan Transcription activator proteins, encoding genes, antibodies; for therapeutic applications.

Texas, Univ. of WO 97/31123 Lyme disease treatment Austin, Texas Vmp-like protein genes of Borrelia, encoded proteins, antibodies, probes; for Lyme disease diagnosis and therapy.

Zeneca WO 97/31118 Protein production plasmids London Plasmids that are highly persistent through successive generations of microbes; for protein production.

—Compiled by Chester A. Bisbee

No Comments